MeSH tree: C05.550.114.865.800
Arthritis includes a range of conditions that affect the joints, from inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis to more common conditions like osteoarthritis. Many people experience pain, ...
Apr 16, 2026
0
7
Scientists investigating the naturally occurring immunopeptide PEPITEM have shown reductions in arthritic joint swelling to a degree comparable to the current standard of care, and reduce the inflammatory changes that cause ...
Apr 13, 2026
0
11
For patients undergoing total hip arthroplasty (THA), those with cutaneous psoriasis (PsC) and psoriatic arthritis (PsA) have an increased risk for complications, according to a study published online March 22 in the Journal ...
Mar 31, 2026
0
2
The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
Mar 11, 2026
0
6
Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, this condition known as psoriatic arthritis can lead to permanent damage to ...
Jan 14, 2026
0
27
Researchers at Academia Sinica have developed the first population-specific polygenic risk score (PRS) models for people of Han Chinese ancestry, achieving unprecedented accuracy in predicting risks for common diseases such ...
Nov 21, 2025
0
22
Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to treatment. EULAR—The European Alliance of Associations for Rheumatology—has released new evidence-based ...
Oct 30, 2025
0
17
Buried in your body is a tribute to a long-dead Italian anatomist, and he is not the only one. You are walking around with the names of strangers stitched into your bones, brains, and organs. We all are.
Oct 27, 2025
0
7
A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in an international clinical trial of more than 200 patients worldwide.
Oct 7, 2025
0
66
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.
Oct 3, 2025
0
17
